Monday, May 13, 2013
Despite decisions by firms like
Atlas Venture and Mohr Davidow to exit the early stage diagnostic space, other
VCs believe the evolution of underlying technologies and the long-term need to
control healthcare costs make it an ideal time to invest.
In a pair of blog posts last
month, Atlas' Bruce Booth painted a pessimistic picture of the outlook for
venture investing in diagnostics.